


The HIV Prevention Pipeline



¹ In Oct 2019, US FDA approved F/TAF for adults and adolescents who have no HIV risk from receptive vaginal sex; still in development for cisgender women.

² Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required. Possible dual pill to market by 2027.

³ Submitted and pending regulatory approval.